These discoveries have suggested that POH1 could become a novel target within the proteasome after the successful development for cancer treatment of proteasome inhibitors that target the chymotrypsin-like activity of the beta-5 subunits of the proteasome core [24, 25]. This evidence concerns the gene PSMD14 and cancer.